Intervention Protocol

You have free access to this content

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors

  1. Marc Arbyn1,*,
  2. Andrew Bryant2,
  3. Pierre PL Martin-Hirsch3,
  4. Lan Xu1,
  5. Cindy Simoens4,
  6. Lauri Markowitz5

Editorial Group: Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group

Published Online: 30 DEC 2013

Assessed as up-to-date: 3 MAR 2011

DOI: 10.1002/14651858.CD009069.pub2


How to Cite

Arbyn M, Bryant A, Martin-Hirsch PPL, Xu L, Simoens C, Markowitz L. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD009069. DOI: 10.1002/14651858.CD009069.pub2.

Author Information

  1. 1

    Scientific Institute of Public Health, Unit of Cancer Epidemiology, Brussels, Belgium

  2. 2

    Newcastle University, Institute of Health and Society, Newcastle upon Tyne, UK

  3. 3

    Royal Preston Hospital, Lancashire Teaching Hospital NHS Trust, Gynaecological Oncology Unit, Preston, Lancashire, UK

  4. 4

    University of Antwerp, Laboratory of Cell Biology and Histology, Antwerp, Belgium

  5. 5

    Centers for Disease Control and Prevention, ESB/DSTDP/NCHHSTP, Atlanta, GA, USA

*Marc Arbyn, Unit of Cancer Epidemiology, Scientific Institute of Public Health, Juliette Wytsmanstreet 14, Brussels, B-1050, Belgium. Marc.Arbyn@wiv-isp.be.

Publication History

  1. Publication Status: Edited (no change to conclusions), comment added to review
  2. Published Online: 30 DEC 2013

SEARCH

References

Additional references

Arbyn 2007
  • Arbyn M, Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. Journal of Clinical Virology 2007;38(3):189-97.
Arbyn 2011
Ault 2004
  • Ault KA, Giuliano AR, Edwards RP, Tamms G, Kim LL, Smith JF, et al. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine 2004;22(0264-410X, 23-24):3004-7.
Ault 2007
  • Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369(9576):1861-8.
Bosch 2002
Bouvard 2009
  • Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens-Part B: biological agents. Lancet Oncology 2009;10(1474-5488 (Electronic), 4):321-2.
Bray 2005
  • Bray F, Carstensen B, Moller H, Zappa M, Zakelj MP, Lawrence G, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiology, Biomarkers and Prevention 2005;14(9):2191-9.
Bray 2005a
  • Bray F, Loos AH, McCarron P, Weiderpass E, Arbyn M, Moller H, et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiology, Biomarkers and Prevention 2005;14(1055-9965, 3):677-86.
Breitburd 1995
  • Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. Journal of Virology 1995;69(6):3959-63.
Brown 2001
  • Brown DR, Bryan JT, Schroeder JM, Robinson TS, Fife KH, Wheeler CM, et al. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. Journal of Infectious Diseases 2001;184(9):1183-6.
Castellsague 2006
  • Castellsague X, Diaz M, De Sanjose S, Munoz N, Herrero R, Franceschi S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. Journal of the National Cancer Institute 2006;98(1460-2105 (Electronic), 5):303-15.
Cogliano 2005
De Sanjose 2007
  • De Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infectious Diseases . 2007;7(1473-3099 (Print), 7):453-9.
Deeks 2001
  • Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG (eds).  Systematic Reviews in Health Care: Meta-Analysis in Context (2nd edition). London: BMJ Publication Group, 2001.
DerSimonian 1986
Dorans 2010
Eggertson 2007
Evans 2001
  • Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA, et al. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. Journal of Infectious Diseases . 2001;183(0022-1899, 10):1485-93.
Ferlay 2004
  • Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5, version 2.0. Lyon: IARCPress, 2004.
Frazer 2004
Galloway 2003
Ghim 2000
  • Ghim S, Newsome J, Bell J, Sundberg JP, Schlegel R, Jenson AB. Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus. Experimental and Molecular Pathology 2000;68(3):147-51.
Harper 2009
Harro 2001
  • Harro CD, Pang Y-YS, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 Virus-Like particle vaccine. Journal of National Cancer Institute . 2001;93(4):284-92.
Higgins 2003
Higgins 2008
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration 2008, issue Version 5.0.1:www.cochrane-handbook.org.
IARC 2004
  • IARC Expert team cervical cancer screening, (Day N, Hakama M, Arbyn M). Cervix Cancer Screening. IARC Handbooks of Cancer Prevention. Vol. 10, Lyon: IARC Press, 2005.
IARC 2007
  • IARC Monograph Working Group on Carcinogenesis (Coglinano V, Baan R, Straif K, Secretan B, El Ghissasi F, Zur Hausen H, et al)  . In: Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F editor(s). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 90: Human Papillomaviruses. Vol. 90, Lyon: IARC Press, 2007:1-670.
Iftner 2003
  • Iftner T, Villa LL. Chapter 12: Human papillomavirus technologies. Journal of National Cancer Institute Monographs 2003;2003(31):80-8.
Initiative 2009
  • Initiative for Vaccine Research of the Department of Immunization VaB. Human Papillomavirus (HPV) Vaccine Background Paper. World Health Organization (WHO). Geneva, 2009:1-249.
Kahn 2009
Kjaer 2009
  • Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prvention Research 2009;2(10):868-78.
Koutsky 2002
Koutsky 2006
Lacey 2006
  • Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006;24(0264-410X (Print), Suppl 3):35-41.
McCredie 2008
  • McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncology 2008;9(5):425-34.
Medeiros 2009
  • Medeiros LR, Rosa DD, Da Rosa MI, Bozzetti MC, Zanini RR. Efficacy of human papillomavirus vaccines: a systematic quantitative review. International Journal of Gynecological Cancer 2009;19(7):1166-76.
Munoz 2004
Ostor 1993
Pagliusi 2004
Parmar 1998
Rambout 2007
  • Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. Canadian Medical Association Journal 2007;177(5):469-79.
Richart 1973
  • Richart RM. Cervical intraepithelial neoplasia. Pathology Annual 1973;8:301-23.
Sant 2009
  • Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. European Journal of Cancer 2009;45(6):931-91.
Schiffman 2005
  • Schiffman MA, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005;337(0042-6822, 1):76-84.
Schiffman 2009
  • Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infectious Agents and Cancer 2009; Vol. 4, issue 1:(1-8).
Schneider 2003
  • Schneider A, Gissmann L. Cervical cancer. The potential role of human papillomavirus (HPV)-specific vaccines in prevention and treatment. American Journal of Cancer 2003;2:1-253.
Sharp 1998
  • Sharp S. Meta-analysis regression. Statatistics Technical Bulletin 1998;7(42):148-55. [MEDLINE: 11989]
Smith 2000
  • Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study. Gynecologic Oncology 2000; Vol. 78, issue 2:97-105.
Solomon 2002
Stanley 2006
Szarewski 2010
Thompson 1999
WHO 2009
  • Initiative for Vaccine Research of the Department of Immunization Vaccines and Biologicals (WHO). Human Papillomavirus (HPV) Vaccine Background Paper. World Health Organization (WHO) 2009:1-249.
Winer 2003
  • Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Journal of Epidemiology . 2003;157:218-26.
Winer 2008
  • Winer RL, Feng Q, Hughes JP, O'Reilly S, Kiviat NB, Koutsky LA. Risk of female human papillomavirus acquisition associated with first male sex partner. Journal of Infectious Diseases 2008;197(0022-1899 (Print), 2):279-82.
Yang 2004